Formulation Licenses
Registered finished dosage forms (FDF), transferable tech packages and in-development in-licensing pipelines · delivered per target-market approval pathway
Formulation (FDF)
Ciclosporin Soft Capsules
Capsules · 10mg; 25mg; 50mg
- Therapy
- Others > Transplantation
- Status
- Official FDF licensing catalog (UB300)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Mycophenolate Mofetil Capsules
Capsules · 250mg
- Therapy
- Others > Transplantation
- Status
- Official FDF licensing catalog (UB299)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Acarbose Tablets
Tablets · 50mg; 100mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB297)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Metformin Hydrochloride and Empagliflozin Tablets
Tablets · 500mg/5mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB296)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets
Tablets · 15mg/500mg; 15mg/850mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB295)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Liraglutide Injection
Injection · 3ml: 18mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB294)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Clarithromycin Tablets
Tablets · 0.25g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB293)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Daptomycin for Injection
for Injection · 0.5g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB292)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Micafungin Sodium for Injection
for Injection · 50mg
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB291)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Caspofungin Acetate for Injection
for Injection · 50mg; 70mg
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB290)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Aripiprazole Orally Disintegrating Tablets
Tablets · 10mg
- Therapy
- Others > Psychiatry
- Status
- Official FDF licensing catalog (UB283)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- To be assessed
Formulation (FDF)
Alogliptin Benzoate Tablets
Tablets · 25mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB282)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Cefuroxime Axetil Tablets
Tablets · 0.125g; 0.25g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB281)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Amoxicillin and Clavulanate Potassium Tablets
Tablets · 0.25g: 0.125g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB280)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Portizomib for Injection
for Injection · 3.5mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB278)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Tropisetron Hydrochloride for Injection
for Injection · 5mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB277)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Reduced Glutathione for Injection
for Injection · 0.6g; 1.2g
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB276)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Imipenem and Cilastatin Sodium for Injection
for Injection · 0.25g: 0.25g; 0.5g: 0.5g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB275)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Piperacillin Sodium and Tazobactam Sodium for Injection
for Injection · 0.5g: 0.125g; 1.0g: 0.25g; 2.0g: 0.5g; 0.5g: 0.0625g; 1.0g: 0.125g; 2.0g: 0.25g; 3.0g; 0.375g; 4.0g: 0.5g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB274)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Ampicillin Sodium and Sulbactam Sodium for Injection
for Injection · 0.5g: 0.25g; 1.0g: 0.5g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB273)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Amoxicillin Sodium and Sulbactam Sodium for Injection
for Injection · 0.5g: 0.25g; 1.0g: 0.5g; 2.0g: 1.0g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB272)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Amoxicillin Sodium and Clavulanate Potassium for Injection
for Injection · 0.5g: 0.1g; 1g: 0.2g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB271)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Dacomitinib Tablets
Tablets · 15mg; 45mg
- Therapy
- Respiratory
- Status
- Official FDF licensing catalog (UB270)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Acetylcysteine Solution for Inhalation
for Inhalation · 10%/4ml; 20%/4ml; 10%/10ml; 20%/20ml
- Therapy
- Respiratory
- Status
- Official FDF licensing catalog (UB269)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Entecavir Tablets
Tablets · 0.5mg; 1.0mg
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB268)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
PegFilgrastim
— · Bulk and injection (PFS): 6mg in 0.6ml
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB265)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Aponermin for Injection
for Injection · 100 mg (8,000,000 U)/vial
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB264)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Cetrorelix Acetate for Injection
for Injection · 0.25mg base
- Therapy
- Others > Women's Health
- Status
- Official FDF licensing catalog (UB254)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Terlipressin Injection
Injection · 0.85mg base
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB253)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- Brazil, Pakistan, Indonesia…
Formulation (FDF)
Zuberitamab Injection
Injection · 100mg/10mL
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB252)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Ceftazidime for Injection
for Injection · 0.5g; 1.0g; 1.5g; 2.0g; 2.5g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB251)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- Japan
Formulation (FDF)
Cefazolin Sodium for Injection
for Injection · 1.0g; 0.5g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB250)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- Japan
Formulation (FDF)
Bimatoprost and Timolol Maleate Eye Drops
Eye Drops · 0.9mg:15mg/3mL
- Therapy
- Ophthalmology
- Status
- Official FDF licensing catalog (UB246)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Malaridine Phosphate Injection
Injection · 80mg/2mL
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB245)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Alendronate Sodium Tablets
Tablets · 70mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB244)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Sodium Cromoglicate Eye Drops
Eye Drops · 0.16g/8mL
- Therapy
- Ophthalmology
- Status
- Official FDF licensing catalog (UB243)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Potassium Chloride Sustained-release Tablets
Sustained-release Tablets · 0.5g; 0.6g
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB242)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Omacetaxine Mepesuccinate Injection
Injection · 1mg/1mL
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB241)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Tafluprost Eye Drops
Eye Drops · 37.5μg/2.5mL
- Therapy
- Ophthalmology
- Status
- Official FDF licensing catalog (UB240)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Acetylcysteine Injection
Injection · 4g/20mL
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB239)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Oxymetazoline Hydrochloride Spray
— · 5mg/10mL
- Therapy
- Others > Otolaryngology
- Status
- Official FDF licensing catalog (UB238)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Magnesium Sulfate Injection
Injection · 2.5g/10mL; 5g/10mL
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB237)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Tobramycin Inhalation Solution
— · 300mg/5mL
- Therapy
- Respiratory
- Status
- Official FDF licensing catalog (UB236)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation
for Inhalation · 50μg/250μg/dose
- Therapy
- Respiratory
- Status
- Official FDF licensing catalog (UB235)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Budesonide Suspension for Inhalation
Suspension · 0.5mg/2 mL; 1mg/2 mL
- Therapy
- Respiratory
- Status
- Official FDF licensing catalog (UB234)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Rupatadine Fumarate Tablets
Tablets · 10mg
- Therapy
- Others > Otolaryngology
- Status
- Official FDF licensing catalog (UB232)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- To be assessed
Formulation (FDF)
Telmisartan and Hydrochlorothiazide Tablets
Tablets · 40mg/12.5mg; 80mg/12.5mg
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB231)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Enzalutamide Tablets
Tablets · 40mg; 80mg
- Therapy
- Others > Men's Health
- Status
- Official FDF licensing catalog (UB217)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States